Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, ONTARIO--(Marketwired - Oct. 19, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
EAST LANSING, MI--(Marketwired - Sep 30, 2015) - Biophotonic Solutions Inc. (BSI), the world leader in automated laser pulse compression, announces that a "MIIPS" automated pulse compression and...
-
TORONTO, ONTARIO--(Marketwired - Sept. 14, 2015) - Spectral Medical Inc. ("Spectral" or the "Company"), (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - Aug. 14, 2015) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXQ), a Phase III company developing the first treatment for patients with septic shock that...
-
EAST LANSING, MI--(Marketwired - Jul 2, 2015) - Biophotonic Solutions Inc. (BSI), the world leader in automated laser pulse compression, announces that company founder Dr. Marcos Dantus will give an...
-
TORONTO, ONTARIO--(Marketwired - May 13, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - May 13, 2015) - Spectral Medical Inc., (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock that...
-
TORONTO, ONTARIO--(Marketwired - April 22, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - April 16, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - April 1, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for...